Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Defining the Objectives of an Analysis of Tarlatamab in Brain Metastases
16+ hour, 29+ min ago (108+ words) Laura Alder, MD, outlined the 3 objectives behind a retrospective analysis evaluating tarlatamab’s efficacy and safety in patients with SCLC and brain metastases. CancerNetwork: What was the rationale for this analysis? Kamel Abou Hussein, MD Sara A. Hurvitz, MD, FACP; Shaina…...
What Are The Biggest Misconceptions About CAR T Cells in Multiple Myeloma?
18+ hour, 6+ min ago (196+ words) Experts outline how certain practices may have an “incomplete understanding” of where the multiple myeloma field is today. Davila is physician–scientist and service chief of the Lymphoma–Myeloma Adoptive Cell Therapy Service at Roswell Park Comprehensive Cancer Center. Richter…...
Emerging RCC Therapies: Casdatifan & PD-1/VEGF Bispecifics Signal Progress
1+ day, 13+ hour ago (154+ words) What emerging RCC therapies could transform clinical practice over the next 3 to 5 years? In an interview with CancerNetwork®, Yu-Wei Chen, MD, MS, an assistant professor of medicine at the University of California San Diego, highlighted promising therapeutic avenues from the…...
Navigating Second-Line CAR-T Candidacy and Sequencing in DLBCL
1+ day, 14+ hour ago (485+ words) The panel worked through candidacy criteria, reviewed the pivotal second-line CAR-T trials, discussed holding and bridging therapy, and applied all of their insights to a real-world case. Zipin noted that disease trajectory also matters: an asymptomatic patient with incidental progression…...
Blood-Based Lung Cancer Screening Tool Earns FDA Breakthrough Device Status
1+ day, 17+ hour ago (273+ words) Data presented at the 2026 AACR Annual Meeting demonstrated the promise of blood-based lung cancer detection via SimpleScreen Lung. SimpleScreen™ Lung, an investigational lung cancer screening test, has received breakthrough device designation from the FDA, according to a news release from…...
FDA Type C Meeting Granted for Pulmonary Metastatic Osteosarcoma Therapy
1+ day, 18+ hour ago (307+ words) Based on 2.5-year OS data from a phase 2b trial, the FDA has granted a Type C meeting to discuss OST-HER2 in fully resected, pulmonary metastatic osteosarcoma. The FDA has granted a Type C Statistical Methods meeting to OS Therapeutics in…...
177Lu-Dotatate Combo Shows Consistent Efficacy Across GEP-NET Subgroups
1+ day, 19+ hour ago (282+ words) NETTER-2 findings showed a consistent reduction in the risk of progression or death with first-line lutetium Lu 177 dotatate in advanced GEP-NETs groups. By primary tumor site, the HR was 0.336 (95% CI, 0.200–0.562) for pancreatic NETs and 0.233 (95% CI, 0.117–0.462) for gastrointestinal NETs. The median…...
Navigating Adjuvant Immunotherapy Selection in Localized RCC
2+ day, 12+ hour ago (159+ words) How should clinicians navigate the evolving adjuvant immunotherapy landscape in localized RCC? In a recent conversation with CancerNetwork®, Yu-Wei Chen, MD, MS, shared insights on balancing efficacy and safety when considering novel combinations: Efficacy Signal: Combining belzutifan (Welireg) with pembrolizumab…...
FDA Approves Iberdomide Combo in Relapsed/Refractory Multiple Myeloma
2+ day, 13+ hour ago (364+ words) Data from the phase 3 EXCALIBER-RRMM trial support the FDA accelerated approval of iberdomide plus daratumumab and hyaluronidase and dexamethasone in this multiple myeloma population. The FDA has approved the CELMoD iberdomide (Zenbexus) in combination with daratumumab (Darzalex) and hyaluronidase-fihj and…...
Stratifying By Baseline Tumor Cell Density Indicates Treatment Effect Heterogeneity in Rectal Cancer
2+ day, 15+ hour ago (472+ words) A post-hoc analysis of the ARISTOTLE trial demonstrated that patients with rectal cancer with high tumor cell density had improved DFS and OS. Sensitivity analyses were restricted to patients with available DNA mutation data revealed that the treatment-TCD interaction was…...